Clinical trials: Metastatic Colorectal Cancer
Metastatic Colorectal Cancer, Colorectal Adenocarcinoma
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
This is a dual arm, open label phase I/II study to evaluate the safety and clinical activity of the combination of durvalumab with CV301 in combination with maintenance chemotherapy for patients with metastatic colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
- Trial name
- NCT03376659
- Testing
- Durvalumab, CV301, Capecitabine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Georgetown University
Colorectal Cancer, Metastases
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
The purpose of this study is to determine the effect of short-duration pre-operative FOLFOX based therapy on postoperative problems after liver surgery for patients with metastatic colorectal cancer.
- Trial name
- NCT00537823
- Testing
- Cetuximab, Bevacizumab, Leucovorin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Washington University School of Medicine
Lymphomas, Solid Tumors
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Background: Methoxyamine hydrochloride (TRC102) is a new cancer treatment drug that may help improve the results of chemotherapy.
- Conditions
- Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma
- Trial name
- NCT01851369
- Testing
- TRC102, CT scan, Lomotil
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer, Colorectal Carcinoma
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
- Trial name
- SIRFLOX (NCT00724503)
- Testing
- SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 530 people
- Sponsor
- Sirtex Medical
Colorectal Cancer, Metastatic Cancer
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after…
- Trial name
- NCT00083616
- Testing
- Panitumumab
- Volunteers
- 185 people
- Sponsor
- Amgen
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Metastatic Colorectal Cancer
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
This study will compare the safety and efficacy of dalotuzumab (MK-0646) in combination with cetuximab and irinotecan in treating participants with wild type KRAS (wtKRAS) metastatic colorectal cancer (CRC) compared to cetuximab…
- Trial name
- NCT00614393
- Testing
- dalotuzumab, irinotecan hydrochloride, cetuximab
- Volunteers
- 558 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen…
- Trial name
- NCT01220999
- Testing
- CS-1008
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Ludwig Institute for Cancer Research
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination…
- Trial name
- NCT00778102
- Testing
- 5-FU, Irinotecan, Leucovorin
- Where
- 19 sites in Austria, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Colorectal Carcinoma
Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.
- Trial name
- NCT01329809
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jennerex Biotherapeutics
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer, MSS
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic…
- Trial name
- PICCASSO (NCT03274804)
- Testing
- Pembrolizumab, Maraviroc
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of cetuximab when given together with pembrolizumab in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02713373
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated…
- Trial name
- ELEVATE CRC (NCT05330429)
- Testing
- Magrolimab, Bevacizumab, Irinotecan
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 77 people
- Sponsor
- Gilead Sciences
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00942266
- Testing
- fluorouracil, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer.
- Trial name
- NCT04786600
- Testing
- Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Colorectal Cancer
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread…
- Trial name
- NCT02164916
- Testing
- cetuximab, irinotecan hydrochloride, vemurafenib
- Where
- 763 sites in United States
- Volunteers
- 106 people
- Sponsor
- SWOG Cancer Research Network